IV Tranexamic Acid did not Reduce Hemarthrosis or Pain in Patients Undergoing ACL Reconstruction

Does Intravenous or Intraarticular Tranexamic Acid (TXA) Reduce Joint Bleeding Following Arthroscopic Anterior Cruciate Ligament (ACL) Reconstruction and Arthroscopic Meniscectomy? Can Intraarticular Use be Harmful to Chondrocytes?

Arthroscopic knee surgery to perform partial meniscectomy and anterior cruciate ligament (ACL) reconstruction is frequent and effective, although a possible complication is postoperative intra-articular bleeding. When this complication occurs, in addition to the associated pain, the patient usually requires an arthrocentesis to avoid loss of joint mobility. Sometimes this problem ends up associ...

Does tranexamic acid decrease bleeding in patients undergoing cardiopulmonary bypass?

We reviewed the records of 66 patients who underwent cardiopulmonary bypass; half of these patients received the plasmin inhibitor, tranexamic acid. The demographics were not different between the group who received tranexamic acid and the group who did not (control group). There was no difference in the heparin or protamine requirements between the two groups. There was a significantly greater...

1344159 - Pharmacokinetics of Tranexamic Acid in Patients Undergoing Cardiac Surgery

Introduction: Tranexamic acid (TXA) is routinely used during cardiac surgical procedures involving cardiopulmonary bypass (CPB) in order to reduce blood loss [1]. Although the optimum dose of TXA has been a subject of debate, a dosing regimen also sometimes referred to as the BART dose remains a popular choice for high-risk cardiac surgery [2]. The pharmacokinetics of TXA during the perioperati...

Commentary: Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery

Etidronate, calcium, or both did not reduce fracture rates in patients with asthma receiving glucocorticoid treatment.

MAIN RESULTS The groups did not differ for mortality (10%, 24%, 16%, and 16% in the etidronate only, calcium only, etidronate plus calcium, and no treatment groups, respectively); symptomatic fractures (6%, 8%, 10%, and 7%, respectively); or symptomatic fractures, semi quantitative vertebral fractures, or both (16%, 18%, 16%, and 20%, respectively). Groups receiving etidronate compared with gro...